Sign inCreate account

Report workspace tools

NCT00126269UNKNOWNanonymous

A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis

Sponsor

Source record

Gustave Roussy, Cancer Campus, Grand Paris

Phase

Source record

Phase III

Modality

AI-normalized

small molecule

Target

AI-normalized

Carcinoma of Unknown Primary (CUP)

Indication / condition

AI-normalized

Carcinoma

Intervention

Source record

cisplatin, gemcitabine

Source & freshness

Source record

NCT ID

NCT00126269

Original source

ClinicalTrials.gov

Source last updated

Sep 08, 2006

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT00126269

Title

A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Status

UNKNOWN

Phase

Phase III

Condition raw

Carcinoma

Condition normalized

Carcinoma

Modality raw

Carcinoma

Modality normalized

small molecule

Target raw

Carcinoma of Unknown Primary (CUP)

Target normalized

Carcinoma of Unknown Primary (CUP)

Interventions

cisplatin, gemcitabine

Public preview

Source record

This clinical trial aims to evaluate the efficacy of cisplatin alone versus cisplatin combined with gemcitabine in patients with carcinoma of unknown primary and a favorable prognosis. The study is sponsored by Gustave Roussy, Cancer Campus, Grand Paris, and is currently recruiting participants.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized Phase III Trial Comparing Cisplatin With or Without Gemcitabine in Patients With Carcinoma of Unknown Primary and a Predicted Favorable Prognosis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT00126269

Status

UNKNOWN

Phase

Phase III

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Executive brief

Investment-Ready Snapshot

This clinical trial aims to evaluate the efficacy of cisplatin alone versus cisplatin combined with gemcitabine in patients with carcinoma of unknown primary and a favorable prognosis. The study is sponsored by Gustave Roussy, Cancer Campus, Grand Paris, and is currently recruiting participants.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedSep 08, 2006
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00126269

Indication

Carcinoma

Modality

small molecule

Target

Carcinoma of Unknown Primary (CUP)

Intervention

cisplatin, gemcitabine

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.